Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.52 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 2/20 | 0.48 |
| ▸ | THRA | P10827 | 1/20 | 0.48 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.48 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL201998 | 1.00 | FAAH (0.53) | FAAHKMT2ASMPD1PARP1PLA2G4B | |
| SCHEMBL203052 | 0.95 | KMT2A (0.56) | FAAHKMT2ASMPD1PARP1PLA2G4B | |
| SCHEMBL204384 | 0.95 | KMT2A (0.56) | FAAHKMT2ASMPD1PARP1PLA2G4B | |
| SCHEMBL203053 | 0.95 | KMT2A (0.56) | FAAHKMT2ASMPD1PARP1PLA2G4B | |
| SCHEMBL12434144 | 0.92 | SMPD1 (0.59) | FAAHKMT2ASMPD1PARP1PLA2G4B | |
| SCHEMBL201450 | 0.87 | KMT2A (0.62) | KMT2ASMPD1PARP1PLA2G4BTHRB | |
| SCHEMBL202206 | 0.87 | KMT2A (0.52) | FAAHKMT2ASMPD1PARP1PLA2G4B | |
| SCHEMBL202205 | 0.87 | KMT2A (0.52) | FAAHKMT2ASMPD1PARP1PLA2G4B | |
| SCHEMBL203104 | 0.86 | SMPD1 (0.68) | KMT2ASMPD1PARP1PLA2G4BTHRB | |
| SCHEMBL203771 | 0.86 | PRSS1 (0.52) | FAAHKMT2ASMPD1PARP1PLA2G4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250179008-A1 | ANTIBACTERIAL AGENTS | TAXIS PHARMACEUTICALS, INC. (US) | 2025-06-05 | — | — | US | disclosed |
| US-20150191420-A1 | ANTIBACTERIAL AGENTS | TAXIS PHARMACEUTICALS, INC. | 2015-07-09 | — | — | US | disclosed |
| US-8865736-B2 | Antibacterial agents | Biota Scientific Pty Ltd (AU) | 2014-10-21 | — | — | US | disclosed |
| US-20130072520-A2 | ANTIBACTERIAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2013-03-21 | — | — | US | disclosed |
| US-20120122918-A1 | ANTIBACTERIAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2012-05-17 | — | — | US | disclosed |
| US-8088791-B2 | Antibacterial agents | Biots Scientific Management Pty Ltd (AU) | 2012-01-03 | — | — | US | disclosed |
| EP-1996180-B1 | BENZAMIDE AND PYRIDYLAMIDE DERIVATIVES AS ANTIBACTERIAL AGENTS | BIOTA EUROPE LTD (GB) | 2011-08-03 | — | — | EP | disclosed |
| US-20100173933-A1 | ANTIBACTERIAL AGENTS | PROLYSIS LTD (GB) | 2010-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122918-A1 | ANTIBACTERIAL AGENTS | ALK, ROS1, ARG1 | FAAH 2422/4885KMT2A 380/4885SMPD1 1528/4885 |
| US-20130072520-A2 | ANTIBACTERIAL AGENTS | ALK, ROS1, NOX1 | FAAH 2356/4885KMT2A 1011/4885SMPD1 1055/4885 |
| US-20150191420-A1 | ANTIBACTERIAL AGENTS | ALK, ARG1, ROS1 | FAAH 2031/4885KMT2A 415/4885SMPD1 1525/4885 |
| US-20250179008-A1 | ANTIBACTERIAL AGENTS | ALK, ROS1, NOX1 | FAAH 2356/4885KMT2A 1011/4885SMPD1 1055/4885 |
| US-20100173933-A1 | ANTIBACTERIAL AGENTS | ALK, ROS1, NOX1 | FAAH 2356/4885KMT2A 1011/4885SMPD1 1055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.